NOVN Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 jul 2023 @ 22:00):

Stats
Dagens volum	6.93M
Gjennomsnittsvolum	1.04M
Markedsverdi	2.64M
EPS	$0 ( 2024-03-28 )
Neste inntjeningsdato	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.112
ATR14	$0.103 (183.93%)

Insider Trading

Date	Person	Action	Amount	type
2023-06-27	Sanders Machelle	Sell	11 553	Common Stock
2023-06-06	John A. Donofrio	Buy	85 000	Restricted Stock Units
2023-06-06	Gay John M.	Buy	200 000	Restricted Stock Units
2023-06-07	Gay John M.	Buy	65 000	Common Stock
2023-06-06	Gay John M.	Buy	65 000	Restricted Stock Units

INSIDER POWER
60.85
Last 97 transactions
Buy: 4 746 863 \| Sell: 340 227

Volum Korrelasjon

Lang: -0.41 (neutral)

Kort: -0.55 (weak negative)

Signal:(24.752) Neutral

Novan Inc Korrelasjon

10 Mest positive korrelasjoner
ARKO	0.981
GLPG	0.962
SIRI	0.955
TTEC	0.953
CLOV	0.953
FOXF	0.95
HCDIP	0.943
WKSP	0.943
LPSN	0.942
SHEN	0.942

10 Mest negative korrelasjoner
VITL	-0.963
AEYE	-0.952
JAN	-0.945
TRMR	-0.943
ROOT	-0.942
PPC	-0.939
THRN	-0.938
CPTA	-0.936
VCTR	-0.936
RZLT	-0.935

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Novan Inc Korrelasjon - Valuta/Råvare

-0.25
( neutral )

-0.78
( moderate negative )

0.00
( neutral )

-0.08
( neutral )

-0.49
( neutral )

0.85
( strong )

Novan Inc Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$0

FY	2023
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$0

FY	2022
Omsetning:	$23.61M
Bruttogevinst:	$16.23M (68.74 %)
EPS:	$-0.890

FY	2021
Omsetning:	$2.96M
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-1.740

Financial Reports:

No articles found.

Novan Inc

Novan, Inc., a pre-commercial nitric oxide-based pharmaceutical company, focuses on dermatology and anti-infective therapies. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. Novan, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.